Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 2/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3770814 | 0.92 | PTGS2 (0.37) | PTGS2RPS6KA1RAB9AL3MBTL1 | |
| SCHEMBL3761760 | 0.90 | PTGS2 (0.38) | PTGS2RPS6KA1 | |
| SCHEMBL3764651 | 0.88 | CYP1A2 (0.35) | PTGS2RPS6KA1L3MBTL1MAOB | |
| SCHEMBL3770661 | 0.88 | RPS6KA1 (0.36) | PTGS2RPS6KA1RAB9AL3MBTL1MAOB | |
| SCHEMBL3772924 | 0.87 | CYP1A2 (0.37) | RPS6KA1L3MBTL1 | |
| SCHEMBL3758606 | 0.83 | RPS6KA1 (0.36) | PTGS2RPS6KA1RAB9AL3MBTL1MAOB | |
| SCHEMBL3764290 | 0.80 | CYP1A2 (0.40) | PTGS2RPS6KA1L3MBTL1 | |
| SCHEMBL3764404 | 0.79 | RPS6KA1 (0.34) | RPS6KA1L3MBTL1MAOB | |
| SCHEMBL3656907 | 0.78 | PTGS2 (0.34) | PTGS2RAB9AL3MBTL1 | |
| SCHEMBL3771871 | 0.78 | L3MBTL1 (0.36) | RPS6KA1L3MBTL1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311790-A1 | AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME | SUMITOMO CHIEMCAL COMPANY LIMITED (JP) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311790-A1 | AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME | ATL3, NAT1, C5 | PTGS2 3626/4885RPS6KA1 1556/4885RAB9A 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.